Showing posts with label ASTRAZENECA. Show all posts
Showing posts with label ASTRAZENECA. Show all posts

Thursday, May 27, 2021

POLITICO NIGHTLY: How much child care went up in your state

 


 
POLITICO Nightly logo

BY RENUKA RAYASAM

Presented by

Emergent BioSolutions

Graphic showing child care costs increased in every state

Annette Choi/ POLITICO

GOING UP — “Thousands of child care providers closed their doors during the pandemic. At the end of last year, 1 in 4 facilities remained closed . The collapse of the child care industry affected the labor market, with more than 10 percent of parents, primarily women, forced to leave their jobs to take care of their children. Although some facilities have reopened in the new year, many are operating on thin margins and decreased, unstable enrollment. The Center for American Progress, a liberal think tank, found that the cost of center-based child care — as opposed to family child care — jumped by 44 percent.

“Prices were bumped up the most in Georgia and Louisiana, with 115 percent and 111 percent increases, respectively. CAP found that the increased costs were driven in part by the new health and safety protections for both children and staff.”

— Graphics reporter Annette Choi, in “Covid’s toll on infrastructure, by the numbers,” coming to POLITICO Thursday as part of the next issue of Recovery Lab, a new project from POLITICO examining policy challenges on the way to recovery. Thursday’s issue focuses on how the pandemic changed how we think about infrastructure.

 

A message from Emergent BioSolutions:

At Emergent, we make things you never thought you’d need — until you do. Until you need to counteract an opioid overdose. Or need protection against smallpox, anthrax, cholera, or botulism. And now, we’re in the fight against COVID-19. At Emergent, we take on public health challenges and work to help protect public health. And that’s why We Go.

 

Welcome to POLITICO Nightly. We’re off on Monday, May 31, for Memorial Day! Reach out with news, tips and ideas for us at rrayasam@politico.com, or on Twitter at @renurayasam.

AROUND THE NATION

WHAT TEXAS TELLS US ABOUT 2022 — Texas lawmakers have passed bills this legislative session that would ban abortion after a fetal heartbeat is detected, allow handguns to be carried without a permit, and require professional sports teams to play the national anthem. Yet with less than a week left, the Republicans who control both chambers haven’t passed a state budget or a response to the deadly winter storm that crippled much of Texas in February.

The Texas legislature is a peculiar place — lawmakers meet for 140 days every other year, and rules are designed to keep bills from passing. But the bills that do get committee hearings and floor votes are an indicator of how Republicans in the country’s largest conservative state anticipate the election dynamics of next year. If the past 130-ish days are any guide, Texas Republicans are very, very confident of their prospects heading into the 2022 midterms.

“Republicans feel like they are holding all the cards in 2022,” James Henson, director of the Texas Politics Project at the University of Texas, told Nightly. Many of the bills passed this session, like the handgun legislation, regularly get introduced but rarely make it to the floor, he said, to shield state lawmakers from tough votes. That changed this year. “The agenda is being dominated by the reactionary wing of the Republican party, and leadership are going with it,” Henson said.

Republican lawmakers maintained their statehouse majorities across the country in 2020, despite President Joe Biden’s win and lots of Democratic money. Now these legislatures hold the keys to congressional redistricting in 22 states.

“We don’t know what their districts will be, but they will try to make them as red as possible,” campaign reporter Ally Mutnick told Nightly.

In Texas, it’s clear that statehouse Republicans are catering to GOP primary voters rather than worrying about general election threats from Democrats. Only 34 percent of Texans support unlicensed carry, for example, compared with 59 percent who oppose it, according to an April University of Texas/ Texas Tribune poll.

Not long ago, the politics of Texas seemed on the cusp of political change. Democrat Beto O’Rourke came close to beating Republican Ted Cruz for a Senate seat in 2018 and, that same year, Democrats won a dozen seats in the state House. In response, Republican state lawmakers spent their 2019 session funding education and cutting property taxes, barely taking up controversial abortion legislation like they do most years.

Then Donald Trump won Texas by almost 6 percentage points in 2020. Biden fell short of Democratic expectations, and Republicans maintained their majorities in the statehouse. No prominent Texas Democrats seem eager to challenge Gov. Greg Abbott or Lt. Gov. Dan Patrick. But for the first time since he’s run for governor, Abbott will face a truly competitive primary.

Republicans in Texas are betting hard that voters will reward them for prioritizing gun-rights legislation over preparing the electrical grid for winter. They might also be trying to lure Trump voters to the polls even when he’s not on the ballot, Ally said.

But the Texas session also taps into a larger debate about which party the culture war helps the most. When Republicans take up bills around transgender rights or abortion, they force Democrats to take tough votes, too. Along the U.S.-Mexico border, for example, there are still anti-abortion Democratic state lawmakers.

There’s a chance that the strategy could backfire. That happened in 2018, a year after Abbott called a special session to debate a bill prohibiting transgender people from using bathrooms that correspond to their gender identity. That November, Democrats got as close they’ve gotten in years to winning statewide races in Texas, and they picked up Congressional and state legislative seats.

Statewide, Biden’s approval rating in April roughly matched that of the Republican governor, Abbott, with 44 percent approving strongly or somewhat of Biden and 43 percent approving strongly or somewhat of Abbott.

 

SUBSCRIBE TO "THE RECAST" TODAY: Power is shifting in Washington and in communities across the country. More people are demanding a seat at the table, insisting that politics is personal and not all policy is equitable. The Recast is a twice-weekly newsletter that explores the changing power dynamics in Washington and breaks down how race and identity are recasting politics and policy in America. Get fresh insights, scoops and dispatches on this crucial intersection from across the country and hear critical new voices that challenge business as usual. Don't miss out, SUBSCRIBE . Thank you to our sponsor, Intel.

 
 
WHAT'D I MISS?

Courtesy of POLITICO

— Biden: Intelligence community split on Covid-19 origin: The president said today that the U.S intelligence community is split between two origin theories for the Covid-19 pandemic, though he notably did not detail the two theories. The president’s statement did note that he had ordered a review of the pandemic’s origins, “including whether it emerged from human contact with an infected animal or from a laboratory accident.” Facebook will also no longer take down posts claiming that Covid was man-made or manufactured, a company spokesperson told POLITICO today.

— 8 dead in shooting at California rail yard: An employee opened fire today at a rail yard serving Silicon Valley, killing eight people before ending his own life, authorities said. The suspect was an employee of the Valley Transportation Authority, which provides bus, light rail and other transit services throughout Santa Clara County, the largest county in the Bay Area, authorities said.

— Bipartisan highway bill advances in Senate: A proposal to spend hundreds of billions of dollars on highways advanced through a Senate committee today even as negotiations on a much bigger package continued to struggle — offering a possible off-ramp for Congress to make some progress on infrastructure this year. The bill approved unanimously by the Senate Environment and Public Works Committee would allocate $311 billion over five years for roads and highways.

— Granholm sells holdings in electric bus maker after GOP criticisms: Energy Secretary Jennifer Granholm sold her holdings in electric bus maker Proterra this week, DOE confirmed to POLITICO today, following criticism from Republicans that she might be profiting from the administration’s push for electric vehicles.

— Karine Jean-Pierre becomes second Black woman behind White House briefing podium: With today’s appearance, Jean-Pierre — the principal deputy press secretary — became just the second Black woman to ever take the podium and the first since Judy Smith did so in 1991 under former president George H.W. Bush. She’s also the first openly gay spokeswoman to field questions in the briefing room.

 

A message from Emergent BioSolutions:

Advertisement Image 

 


ASK THE AUDIENCE

FLUSH WITH DEMAND — Nightly’s Tyler Weyant writes:

Memorial Day is coming up, and like millions of Americans, I’ll be traveling, visiting with friends I haven’t seen in more than a year. But, while perusing the local paper in our destination of Portland, Me., I was met with some crappy news: Maine has a shortage of porta-potties.

While Edward D. Murphy’s article in the Portland Press Herald might seem at first to be merely a springboard for puns like that one, the supply of portable toilets nationwide mirrors a nationwide story across multiple industries.

Among the headwinds facing the dwindling national strategic reserve of porta-potties, according to Karleen Kos, executive director of the Portable Sanitation Association International, the portable toilet trade association: A shortage in plastics to make portable toilets, thanks in part to international petroleum market instability and the winter Texas freeze. Shortages in truck drivers to deliver both new toilet units to companies and rented units out to sites. And a demand for both toilets and handwashing stations brought on by Covid safety concerns.

In Warrenton, Va., Potter’s Potties owner Bucky Potter said his Northern Virginia business has seen these trends on the ground, with manufacturers warning of raw material outages for new toilets, paired with a springtime increase in rental inquiries of 60 percent, double the usual seasonal increase.

Beyond the shortages, Kos sees an industry that may be able to — why not — clean up its image. The public will expect a higher level of maintenance and cleanliness post-Covid, she said.

“People have varying opinions on portable toilets, but most often people see them as a necessary evil. They don’t see them as a respected alternative,” she said. “The idea that you would clean a toilet at a big box store hourly, but you would leave a plastic box with a tank in it unattended for a week at a time, that’s why portable toilets sometimes aren’t very pleasant.”

This is often a budget issue, Potter said. Construction sites, for example, have OSHA regulations that require a toilet for every 10 full-time workers, and will therefore go with the cheapest option, regardless of quality. If OSHA were to lower that requirement to 5 workers for every toilet, he said, which some local governments did during Covid, or increase sink regulations, it might help change the public’s perspective.

Still, when it comes to portable toilets, people are just looking for a decent, dignified moment. “Nobody is asking for gold lamé gildings in their toilets,” Kos said. “They just don’t want it to be unpleasant.”

Nightly asks you: Portable toilets aren’t the only thing there is a shortage of, as news stories come out seemingly every day bemoaning a lack of items from Chick-fil-A sauce to gasoline. What pandemic shortages have you seen in your community? Send us your answers on our form, and we’ll include select responses next week.

AROUND THE WORLD

‘STATE-SPONSORED HIJACKING’ — Ryanair 4978 started like any flight, until the plane was forced to land in Minsk at the behest of Belarusian President Alexander Lukashenko to arrest a dissident journalist. In the latest POLITICO Dispatch, POLITICO Europe’s David M. Herszenhorn talks about why the EU and the US might have to rethink their responses to the incident.

Play audio

Listen to the latest POLITICO Dispatch

AN OXFORD DEBATE — Today saw the first public airing of a bitter dispute between AstraZeneca and the European Commission — backed by the 27 EU member states. The fight began back in January, when the drugmaker announced its first delivery delays and resulted essentially in a divorce between the two once-optimistic partners months later.

The EU’s lawyers argued that the company didn’t try hard enough to supply the EU and now needed a judge to get the company to hurry up. AstraZeneca’s lawyers countered that both parties were well aware that they were signing a contract for a brand new coronavirus vaccine that would be difficult to produce on a global scale, let alone gain approval from regulators.

Often, the hearing descended into a back-and-forth spat over whether the Anglo-Swedish company betrayed its EU contract by giving more doses to the U.K.

Under gilded paintings that depicted one man sitting on a throne and stabbing another man in the back, a rotating group of EU lawyers pointed to how AstraZeneca delivered 37 percent of the doses it promised to the U.K. but only 18 percent of the EU’s contract.

Still, it was unclear what all the fighting in a courtroom would achieve. The Commission argues its case is to secure more doses as soon as possible, but its lawyers also included financial penalties — €10 per dose per day each vaccine is delayed — if a court rules in favor of the EU but AstraZeneca is unable to stick to a three-month postponed schedule.

And AstraZeneca, which has tried to be the main producer of vaccines for the world rather than the world’s wealthiest, questioned why the bloc needed so many vaccines immediately.

 

SUBSCRIBE TO WEST WING PLAYBOOK: Add West Wing Playbook to keep up with the power players, latest policy developments and intriguing whispers percolating inside the West Wing and across the highest levels of the Cabinet. For buzzy nuggets and details you won't find anywhere else, subscribe today.

 
 
NIGHTLY NUMBER

45 percent

The increase in the number of people getting vaccinated against Covid-19 in Ohio after Gov. Mike DeWine announced the $1 million Vax-a-Million lottery, the governor said today on CNN. The first winners were announced tonight. H/t Olivier Knox.

PARTING WORDS

OBAMA’S REGRETS — Former President Barack Obama said today that while he was “wildly enthusiastic” about the resurgence of activism during his presidency, he often felt limited by “institutional constraints” that kept him from commenting on federal investigations into certain killings, including of the Black teenagers Trayvon Martin and Michael Brown.

Obama said that, unlike Trump, he followed the notion that the Justice Department was independent, Myah Ward writes.

“I did not in any way want to endanger their capacity to go in, investigate and potentially charge perpetrators, which meant that I could not come down or appear to come down decisively in terms of guilt or innocence,” Obama said in a virtual gathering with the My Brother’s Keeper Leadership Forum, where he discussed a year of activism following the murder of George Floyd in May 2020.

Obama said he was proud of how his administration reshaped the Justice Department’s approach to these problems, but added that he found it difficult to convert “passion and concern” into political action, not only at the federal level but also at the state and local levels, where many criminal justice and policing decisions are made.

“Because keep in mind, in 2012 I won. But I didn’t win congressmen, and we didn’t win a bunch of governorships back. We didn’t win a bunch of state legislators back,” Obama said. “And so, all the reform initiatives that we were coming up with, and the ideas that had been generated, we weren’t able to translate into as bold a set of initiatives as I would have wanted.”

Did someone forward this email to you? Sign up here.

 

A message from Emergent BioSolutions:

At Emergent, we make things you never thought you’d need — until you do. Until you need to counteract an opioid overdose. Or need protection against smallpox, anthrax, cholera, or botulism. And now we’re in the fight against COVID-19. At Emergent, we take on public health challenges. For over 20 years, we have produced therapies and vaccines to help protect public health. And that’s why We Go.

 
 

Follow us on Twitter

Renuka Rayasam @renurayasam

Chris Suellentrop @suellentrop

Tyler Weyant @tweyant

Myah Ward @myahward

 

FOLLOW US


 POLITICO, LLC 1000 Wilson Blvd. Arlington, VA, 22209, USA




Thursday, April 8, 2021

POLITICO NIGHTLY: Say it ain’t so, Amtrak Joe

 



 
POLITICO Nightly logo

BY MICHAEL GRUNWALD

Presented by

With help from Joanne Kenen

TWITTER TO ARCHIVES: NO @REALDONALDTRUMP FOR YOU — Twitter will not allow the National Archives to make former President Donald Trump’s past tweets from his @realDonaldTrump account available on the social media platform, the company told POLITICO today, in the latest display of Silicon Valley’s power over communications channels used by the U.S. government. Read Quint Forgey’s full report.

TRAINWRECK — Amtrak’s most prominent passenger is now the most powerful man on earth, and he just unveiled a massive infrastructure plan with a whopping $80 billion for rail. No wonder Amtrak just unveiled a huge expansion plan that would serve 160 new cities.

Map of proposed Amtrak train routes in the U.S.

Amtrak

But in the words of the president known as Amtrak Joe, the commuter-in-chief whose name graces the Joseph R. Biden Jr. Railroad Station in Wilmington: C’mon, man.

With all the chronic problems facing Amtrak’s existing network of slow and sporadic trains that struggle to attract riders and revenues, why should it be a national priority to extend the network to sleepy communities like Christianburg, Va. (population 22,163) or Rockland, Me. (population 7,178)? Is North Carolina really clamoring for service from Asheville to Salisbury? Is there any reason for Amtrak executives to propose a new route from New York City to President Biden’s beloved birthplace of Scranton, Pa., other than the obvious reason?

Politics is the reason Amtrak already operates in 46 of the lower 48 states, even though few of them have the population densities that make inter-city rail work so well in much of Asia and Europe. Scattering trains across the country helps bring lawmakers on board, the infrastructure equivalent of the Pentagon distributing contracts for a single jet to hundreds of congressional districts. Amtrak’s new 2035 Vision reveals a desire to keep spreading rail money around like peanut butter — to plausible destinations like Las Vegas and Phoenix but also to head-scratching destinations like Allentown and Cheyenne, which would make Wyoming the 47th state with a station.

“There’s always a political tax on the geography of infrastructure investment,” says Adie Tomer, an infrastructure expert at the Brookings Institution. “You just don’t want the tax to get too big.”

So before Amtrak fantasizes about new lines to Pueblo, Colo., and Eau Claire, Wis., it ought to focus on upgrading its most important and successful line, the Northeast Corridor between Boston and Washington, D.C.

It’s the only Amtrak route that runs an operating profit. It’s the only Amtrak route that runs primarily on tracks that Amtrak owns. And it includes four of Amtrak’s five busiest stations as well as the one named for the president. With top speeds of 150 miles per hour, it’s as close as Amtrak gets to high-speed rail. Its average speeds are less than 90 miles per hour, but if you ignore the frequent delays, spotty Wi-Fi and lousy food, it at least vaguely resembles the train service you might find in Germany or Japan.

The Northeast Corridor desperately needs new investment to repair the bottlenecks that keep it so far below its top speeds, especially its decrepit tunnels under the Hudson River. Amtrak already shuttles three times as many passengers between Washington and New York as the airlines do. Upgrading its aging infrastructure could reduce trip times and improve reliability enough to draw even more travelers out of planes or cars.

Amtrak seems to recognize the urgency of this problem, noting in its vision statement that the Northeast Corridor has “dozens of bridges, stations and tunnels … in need of immediate replacement or rehabilitation.” But by some estimates, just bringing the Northeast Corridor up to a state of good repair could vacuum up more than half the American Jobs Plan’s $80 billion rail budget. Upgrading the corridor to approach true high-speed rail could vacuum up all of it.

Then-Democratic presidential nominee Joe Biden boards a campaign train after a stop at Pittsburgh Union Station on Sept. 30, 2020, in Pittsburgh.

Then-Democratic presidential nominee Joe Biden boards a campaign train after a stop at Pittsburgh Union Station on Sept. 30, 2020, in Pittsburgh. | Getty Images

Amtrak’s plan was not vetted by the White House; in fact, POLITICO Pro’s Tanya Snyder reported today that the Biden Administration does hope to spend half its rail money upgrading the Northeast Corridor, reserving most of the rest for Amtrak lines and other “intercity passenger rail.”

The administration has suggested a sensible fix-it-first approach to the nation’s roads and bridges, proposing to finance long-overdue repairs rather than build new roads to nowhere. Transportation experts believe that approach makes even more sense for rail. Americans rarely even contemplate taking a long-distance train unless it’s faster than driving and departs frequently enough that it doesn’t require much trip planning. And while experts do see potential for a few new high-speed routes between big cities — like Los Angeles to Las Vegas, or Houston to Dallas — those wouldn’t necessarily need to involve Amtrak.

Amtrak seems to want to have it all — long-overdue repairs, new high-speed lines and also new slow-speed trains to Rockford, Ill., and Reading, Pa. Jeff Davis, a senior fellow at the Eno Center for Transportation think tank, was surprised to see the 2035 Vision included a Minneapolis-Duluth line that former Minnesota congressman Jim Oberstar used to push when he chaired the House Transportation Committee.

“You know, Mr. Oberstar passed away — and Duluth is a long way off,” Davis said.

The politics of Amtrak is a lot like the politics of the U.S. Postal Service. Politicians attack both as money pits, but they also insist on propping up little-used money-losing train routes and post offices in their states. Congress will ultimately decide the details of the American Jobs Act, and some Democrats might like Amtrak’s plan for dubious new lines in swing states like Georgia, Arizona and Pennsylvania.

Yes, but as a certain passenger who logged more than 2 million miles on the Northeast Corridor likes to say: “Show me your budget, and I’ll tell you what you value.”

The value of Amtrak isn’t to extend passenger rail everywhere. It’s to provide efficient and convenient passenger rail in some places that improves American mobility while reducing carbon emissions from cars and planes.

Amtrak had a record 32 million riders in 2019, but that crashed to 17 million in 2020 because of the pandemic. Spending money to upgrade the lines Americans actually use could help reverse that trend. Spending money to build a new line from Oklahoma City to Newton, Kan., would be typical Washington malarkey.

Welcome to POLITICO Nightly. Reach out with news, tips and ideas for us at mgrunwald@politico.com and rrayasam@politico.com, or on Twitter at @mikegrunwald and @renurayasam.

A message from UnitedHealth Group:

Greater diversity among health care professionals can improve patient care, leading to better health outcomes. That’s why UnitedHealth Group is investing in a 21st century health workforce that ensures all communities have access to high-quality care. Learn more.

 
FIRST IN NIGHTLY

FOOD FIGHT — Seven months into the school year, millions of low-income families are still waiting for billions of dollars in federal food aid that was supposed to compensate them for school meals that were missed during remote learning, Helena Bottemiller Evich writes.

The Biden administration recently accelerated the rollout, but the program remains mired in bureaucracy. Nearly half of states still haven’t sent any of the money out, even as child hunger rates remain near record highs.

Congress first created the $2 billion-a-month program, called Pandemic-EBT, or P-EBT, last spring during the early days of the pandemic when schools were shuttered to give households a debit card to buy groceries. Lawmakers extended it for the whole school year in September as families continued to grapple with school disruption.

The slow rollout shows the pitfalls of standing up new bureaucratic channels during an emergency. It also could be exacerbating alarmingly high rates of child hunger. One in six households with children is reporting they do not have enough to eat, a rate much higher than even in the depths of the Great Recession. Researchers found the first round of the aid that went out last year alleviated hunger for millions of children.

It’s a sharp contrast to other forms of federal aid that have made their way to consumers and businesses rapidly during the crisis. Last year, the federal government was able to begin the Paycheck Protection Program and get hundreds of billions in loans out to businesses in a matter of weeks. Stimulus checks, which can be directly deposited into accounts, have also gone out quickly to millions.

 

JOIN AN IMPORTANT CONVERSATION, SUBSCRIBE TO "THE RECAST" NEWSLETTER: Power dynamics are shifting in Washington and across the country, and more people are demanding a seat at the table, insisting that all politics is personal and not all policy is equitable. "The Recast" is our twice-weekly newsletter that breaks down how race and identity are recasting politics, policy and power in America. Get fresh insights, scoops and dispatches on this crucial intersection from across the country and hear from important new voices that challenge business as usual. Don't miss out, SUBSCRIBE . Thank you to our sponsor, Intel.

 
 
WHAT'D I MISS?

— Report: Accuser says Cuomo groomed her, urged her to stay silent: The female staff member who alleges New York Gov. Andrew Cuomo groped her inside the governor’s mansion in November told the Albany Times Union that he had groomed her over time and later urged her to stay silent about their interactions.

— Trump claims Gaetz ‘never asked me for a pardon’: In a two-sentence statement today , Trump stressed that Gaetz “has totally denied the accusations against him.” Trump’s brief statement broke silence from Trump and his allies on the allegations against Gaetz, one of the former president’s strongest supporters in Congress.

— Biden to unveil long-awaited executive actions on guns: The announcement comes nearly three months into Biden’s term in office, a delay that had frustrated activists who wanted the president to fulfill a campaign pledge to take action on gun violence on his first day in office. That frustration grew after a slate of mass shootings in Colorado, Georgia and California.

 

Advertisement Image 

 
FROM THE HEALTH DESK

VACCINATION AND LONG COVID — You’ve probably heard, and in fact Nightly’s Myah Ward has told you , about the intriguing signs that Covid vaccines are relieving symptoms in some, though not all, long Covid sufferers. Whether that’s a permanent fix, or just a respite, and why it helps some but not others isn’t yet clear.

But will vaccination help prevent new cases of long Covid? POLITICO’s health care editor at large Joanne Kenen began asking scientists about that after she heard some older people on a Zoom call — at risk because of their age — say they didn’t see any point to getting the vaccine because they could still get a mild or asymptomatic case of Covid and then get the chronic, long form. (Joanne bit her tongue, but let’s get back on task.)

Not many people are studying this aspect of vaccination apparently — or the data is still so thin at this early stage that they weren’t willing to be quoted yet. The CDC findings that the Pfizer and Moderna shots were 90 percent effective in preventing infection, including mild or asymptomatic infection, are good news. People who don’t get infected with the virus, even asymptomatically, won’t get long Covid. But we still have a lot to learn. “We just don’t know,” is the response Joanne kept hearing.

Akiko Iwasaki, an immunologist at Yale, is the exception. Her research is preliminary, but she is fairly optimistic that vaccinations will lessen the risk. Iwasaki outlined three possible mechanisms that might be causing long Covid in a Medium post. One is “a persistent viral reservoir” in the patient’s tissue. Two is a “viral ghost,” fragments of the virus’s genetic material or proteins that stick around after the virus is cleared but can still stimulate the immune system. Three is an autoimmune response.

“I suspect that people with long Covid have varying degrees of all three mechanisms taking place,” Iwasaki wrote. “Thus, long Covid consists of multiple types of diseases.”

Vaccination, she told Joanne later in an email, should “significantly reduce the risk of getting long Covid.”

“The vaccine will induce robust antibodies and T cell responses to the virus,” Iwasaki said. “Even if you were to then get infected, the symptoms will be mild and short. To establish long covid, as I discussed in that piece, there needs to be either establishment of viral reservoir, or autoimmunity. Preexisting antibodies and T cells will quickly control the virus, preventing persistent viral reservoir. Preexisting antibodies and T cells will quickly control the virus, preventing persistent viral reservoir. Preexisting immunity will also prevent significant replication and spread of the virus, which is likely required to induce autoimmune responses.”

In short — we don’t know yet. But there’s good reason to hope.

ASK THE AUDIENCE

Nightly asks you: As people begin to plan travel for the spring and summer, tell us what podcasts we should listen to when we finally hit the road? Use the form to give us your answer, and we’ll use select responses in Friday’s edition.

THE GLOBAL FIGHT

BREXIT, BUT FOR ASTRAZENECA — The perplexing headlines regarding the Oxford/AstraZeneca vaccine continued today in Europe, where the EU and U.K. made dueling announcements about the vaccine’s use.

— EU: The European Medicines Agency today backed continued use of the Oxford/AstraZeneca vaccine in all adults, in a statement confirming a “possible link” to “very rare” cases of blood clotting. The statement, following a fresh review by the regulator’s safety committee, said the overall benefits of the vaccine in protecting against the coronavirus still outweigh the risks. The vaccine remains approved in the EU for anyone over the age of 18.

— U.K.: The U.K. concluded that adults under 30 should be offered an alternative to the Oxford/AstraZeneca vaccine, after reviewing cases of rare blood clots. Jonathan Van-Tam, deputy chief medical officer for England described the move as “a course correction” for the U.K. vaccination program, meaning that younger adults will be offered alternative vaccines instead.

 

STEP INSIDE THE WEST WING: It actually is infrastructure week ... and it will be for a while. What is the administration’s plan to get its top legislative priority through Congress? Add Transition Playbook to your daily reads for details you won't find anywhere else about the state of play of the administration's top priorities and biggest challenges. Track the people, policies and power centers of the Biden administration. Subscribe today.

 
 
NIGHTLY NUMBER

$85 million

The amount of money Trump’s political action committee, Save America PAC, currently has in the bank, according to a Trump adviser. The former president is reigniting his small-dollar fundraising operation for the first time since leaving the White House, part of his ramp-up to the 2022 midterm elections and a potential 2024 comeback bid.

PARTING WORDS

A GIULIANI IN ALBANY? Andrew Giuliani, the son of Trump lawyer and former New York City Mayor Rudy Giuliani, said in an interview today that he is “seriously considering” a run for governor in 2022 and spoke with Trump earlier this week about his political ambitions, Gabby Orr and Meridith McGraw write.

“I did speak with President Trump on Monday and it was a great conversation,” Giuliani said. “We talked about New York politics and went through the numbers on this and I explained to him where I think I would be able to make inroads that no other potential candidate would be able to.”

A blessing from Trump would go a long way for any Republican candidate running in a GOP primary. That may be particularly true in New York, where the former president built his real estate empire and made his name before decamping to Florida in his post-presidency.

But for Giuliani, a former White House official and frequent golf partner of the 45th president, getting Trump’s backing is no slam dunk. The former president is said to be partial to Rep. Lee Zeldin (R-N.Y.), a longtime GOP congressman and friend of the Trump family, who has been floated as a possible candidate himself.

A message from UnitedHealth Group:

United Health Foundation’s Diverse Scholars Initiative is building a 21st century health workforce that ensures all communities have access to high-quality care.

We’re proud to have supported nearly 3,000 scholars who will become part of the health workforce and increase access to care, address health disparities and improve health outcomes.

Learn more.

 

Did someone forward this email to you? Sign up here.

 

Follow us on Twitter

Renuka Rayasam @renurayasam

Chris Suellentrop @suellentrop

Tyler Weyant @tweyant

Myah Ward @myahward

 

FOLLOW US


 POLITICO, LLC 1000 Wilson Blvd. Arlington, VA, 22209, USA




Monday, March 29, 2021

RSN: FOCUS: Drug Patents and Big Pharma Are Slowing Down the Vaccine Rollout and More

 

 

Reader Supported News
29 March 21

It's Live on the HomePage Now:
Reader Supported News


OFF THAT COUCH AND HELP OUT … YES YOU! We have overwhelming numbers in our favor. What we need “you” to say is, “yes me.” I’ll be the one. It’s never fair, it’s never ideal or perfect. The only way to make it work is reject failure and take responsibility. Yes you. Who is better suited? / Marc Ash, Founder Reader Supported News

Sure, I'll make a donation!


FOCUS: Drug Patents and Big Pharma Are Slowing Down the Vaccine Rollout and More
A health care worker administers a dose of the Pfizer-BioNTech COVID-19 vaccine. (photo: Roger Kisby/Bloomberg/Getty Images)
Dean Baker, Jacobin
Baker writes: "Our current model of pharmaceutical research is based on patent monopolies designed to enrich drug company executives and shareholders. But there's a better way to develop new drugs and vaccines, based on public funding and open-source research."


t is often said that intellectuals have a hard time dealing with new ideas. Unfortunately, for purposes of public debate, open-source government funding of drug development is a new idea, and people in policy positions seem to be having a very hard time understanding it. So, I will try to write this post in a way that even a policy wonk can figure it out.

The basic idea of government-funded research should not be hard to grasp since the government already funds a large share of biomedical research. The National Institutes of Health gets over $40 billion a year in federal funding, with the Biomedical Advanced Research and Development Agency (BARDA) and other government agencies getting several billion more. This puts the government’s total spending in the $45 to $50 billion range, compared to a bit over $90 billion from the industry. So the idea that the government would fund research really should not be that strange.

Most of the public funding does go to more basic research, but there are plenty of instances where the government has actually funded the development of new drugs and also done clinical testing. But under the current system, most of the later stage funding does come from the industry and is funded through patent-monopoly pricing. Relying on open-source, government-funded research for later-stage development and testing would be a major change.

The Outlines of a System of Government-Funded Research

To my view, the best way for the government to support the development of new drugs is through long-term contracts (10–12 years), which would be awarded through competitive bids for research in specific areas, like cancer or heart disease. The plan would be for the contracts to be relatively large, with the idea that the winners would be comparable to prime contractors for the military. (I describe this system in somewhat more detail in chapter 5 of Rigged [it’s free].)

Major military contractors, like Lockheed or Boeing, typically contract out to many smaller companies in specific areas. This is a good model. Most of the major innovations in the development of new drugs have come from start-ups, who are often bought out by major pharmaceutical companies like Pfizer or Merck. The winners of prime contracts under this system would be foolish not to look to award contracts to innovative start-ups to ensure they have something to show for their work.

One condition that would apply to both prime contractors and any subcontractors is that all research findings would have to be fully open, meaning that they are posted on the Internet as soon as practical. This would apply both to preclinical research and the results of clinical trials. The posting of trial results would mean that researchers around the world would be able to independently analyze the data and assess the effectiveness and risks of drugs and vaccines for different populations.

I have had many people ask me what the incentive would be for the companies that win contracts to actually innovate as opposed to just spinning their wheels. Since they presumably would want to renew their contracts when they expire, that should provide substantial incentive for them to have something to show.

Also, the researchers would presumably want to actually do something with their time rather than just looking to collect a paycheck. I have also suggested having a large pot of money (e.g., $200 million a year) to pay out as prizes, similar to a Nobel Prize. If a researcher, or group of researchers, has a major breakthrough that will radically improve the treatment of heart attack victims, why not give them $10 million? But this prize would be on top of their ordinary pay, not a replacement.

People have often raised the problem of political influence determining the awarding of contracts. There is always a risk of political interference, which of course arises under the current system as well. One advantage of this system is that the full public posting of results should at the least make blatantly political decisions difficult, if not impossible. If a company had received $30 billion to research lung cancer over a ten-year period and had nothing to show in terms of new drugs or major innovations, it would be hard to justify another long-term contract to the same company.

All of the drugs developed through this system (the funding would include carrying new drugs through the FDA approval process) would be available as generics from the day they are approved. This would mean that new drugs that may sell for thousands of dollars, or even tens of thousands of dollars, under the patent monopoly system are likely to sell for ten or twenty dollars. Drugs are rarely expensive to manufacture and distribute; under a system of government-financed, open-source research, they would also be cheap to buy.

Government Funding in the Pandemic

The pandemic provided a great opportunity to experiment with open-source government funding. While we did the government funding part, with the US government alone putting up $10 billion through Operation Warp Speed, we did not get the open-source part. The government effectively paid for much or all of the research, but still gave private companies patent monopolies.

Ideally, we would have negotiated an international pact, where all countries would contribute to research, based on their size and relative wealth, and all findings would be fully open to researchers around the world. I’ve heard people object that it’s difficult to negotiate these sorts of deals, and we needed to act in a hurry. Some people have also insisted that China and Russia never would have agreed to such a deal.

On the first point, it really should not have taken very long to negotiate a pact. We are throwing money around all over the place. No one thinks that we are getting things exactly right. Some industries and individuals are getting compensated in ways that they probably don’t need or deserve and, undoubtedly, some people are being left behind. If the United States or some other country chips in 20 percent too much or too little, it would be chump change relative to the costs of the pandemics and various rescue packages being put forward.

As far as including China and Russia in a deal, I have no idea whether they would be anxious to join if given the opportunity. They have joined in many other international agreements, so there would be no prima facie reason to assume that they would not want to be parties to this sort of arrangement. We also can’t know for certain that they could be counted on to contribute their agreed-upon share and to make results fully open, but as a practical matter, both countries have been reasonably good about adhering to other agreements to which they are a party.

It would have been enormously advantageous if China and Russia would have been included in a pact with open-source research. Ideally, if all the successful vaccines were fully open, including their production processes, manufacturers anywhere in the world that had the ability to produce these vaccines could have done so.

And they could have begun to ramp up production even before the vaccines had been determined to be safe and effective. The cost of manufacturing one billion vaccines that turned out not to be approved is trivial, in both lives and money, compared to the cost of waiting to have one billion vaccines become available so that they can be administered.

While we can never know how much more quickly we could have learned about the effectiveness of vaccines and arranged their distribution, in an open-source world, we can have some idea just from what we have learned over the last several months.

For example, Pfizer discovered that it is possible to get six shots out of a standard shipping vial, not the five they originally believed. This means getting 20 percent more vaccines. If this knowledge was available sooner, it might have meant hundreds of thousands or even millions of additional vaccines.

There is also evidence, based on data from Israel, that the Pfizer vaccine is highly effective after just one shot. It is possible that if all the clinical trial data was fully public that this result could have been discovered sooner. This would have allowed countries to adopt a one-shot strategy with the second shot coming after most people had received their initial shot.

Pfizer also discovered that its vaccine can be kept in a normal freezer for up to two weeks, instead of requiring super-cold storage. If this was known sooner, it would have greatly facilitated the storage and distribution of the vaccine.

And Pfizer reported last month that it had discovered a way to alter its production process to nearly double its output of vaccines. It’s hard to believe that if engineers all over the world were familiar with Pfizer’s production process, not one would have been able to realize this potential improvement more quickly.

We also got an interesting lesson about incentives with reports that AstraZeneca cherry-picked the data it presented to the Food and Drug Administration (FDA) to gain approval of its vaccines. While AstraZeneca denies the charge, this problem would not exist in an open-source world.

First, the company that developed a vaccine or drug would have no special incentive to see it approved if it was not safe and effective. While it would like to have something to show when a contract came up, the risk of having a drug approved that later turned out not to be safe or effective would likely far exceed any potential benefit.

More importantly, the clinical trials would not be under its control. The data from these trials would be fully public so that any researcher anywhere in the world could analyze it independently. If the FDA or some other regulatory agency misread the data and made the wrong call, it is virtually certain that independent researchers would be able to recognize the mistake and call public attention to it.

We would not have stories like Purdue Pharma misleading physicians about the addictiveness of its opioids. Under a system of open-source research, they would have neither the incentive nor the opportunity.

If People Act the Way Economic Theory Predicts, We Should Want Open-Source Research

Economists always want to look at the incentive structures that we create with our policies. While patent monopolies do create incentives to develop drugs and vaccines, they also create incentives to keep as much research as possible secret, so as not to benefit competitors. The huge markups allowed by patent monopolies also create an enormous incentive for drug companies to lie about the safety and effectiveness of their products.

Open-source, publicly funded research radically alters the structure of incentives. The incentive is to try to have research results spread as widely and quickly as possible in the hope that others can build on them. And there is no incentive or opportunity to push drugs that are unsafe or ineffective. This is a big deal.


READ MORE


Contribute to RSN

Update My Monthly Donation




Tuesday Afternoon Updates – Error 404: President Not Found

                                                                                                                                            ...